Abstract
Despite promising results in initial trials, renal denervation failed to achieve its efficacy end points as a treatment for resistant hypertension in the SYMPLICITY HTN-3 trial, the largest trial of this treatment to date (N Engl J Med 2014; 370:1393-1401). Is renal denervation dead, or will future trials and newer technology revive it?.
Cite
CITATION STYLE
APA
Shishehbor, M. H., Hammad, T. A., & Thomas, G. (2017). Renal denervation: What happened, and why? Cleveland Clinic Journal of Medicine, 84(9), 681–686. https://doi.org/10.3949/ccjm.84a.14129
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free